{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:54:25Z","timestamp":1790927665915,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecol Obstet Invest"],"abstract":"<jats:p>Objectives: The function of miR-382-5p in polycystic ovary syndrome (PCOS) remains unclear. This study aimed to investigate the potential regulatory mechanisms of the miR-382-5p\/DNA topoisomerase I (TOP1) axis in PCOS. Design: The study included 120 healthy controls and 120 PCOS patients. Serum samples were collected from all participants. Human granulosa-like cell line KGN was cultured in vitro and treated with insulin. Methods: Reverse transcription quantitative PCR (RT-qPCR) was used to detect RNA expression; the Cell Counting Kit-8 (CCK-8) assay was used to assess cell proliferation; flow cytometry was used to detect cell apoptosis; and enzyme-linked immunosorbent assay (ELISA) was used to measure the protein levels of Bcl-2, Bax, and Cyclin D1. The protein content of TOP1 in KGN cells was detected by Western blotting. RNA immunoprecipitation (RIP) and dual-luciferase assays were used to validate the binding relationship. Results: Serum miR-382-5p levels were significantly downregulated in PCOS patients, demonstrating good diagnostic value and showing a negative correlation with key clinical indicators of PCOS. In vitro experiments confirmed that, under insulin-induced conditions, overexpression of miR-382-5p significantly inhibited insulin-induced abnormal proliferation of granulosa cells, downregulated the protein of cyclin D1, and simultaneously promoted apoptosis by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-2. This mechanism was associated with the direct targeting and inhibition of topoisomerase I (TOP1). In PCOS patients, elevated TOP1 mRNA and protein expression correlated negatively with miR-382-5p levels. Overexpression of TOP1 significantly reversed the antiproliferative and proapoptotic effects of miR-382-5p. Limitations: The verification of the miR 382 5p\/TOP1 regulatory mechanism was limited to incomplete in vitro cell experiments and non-standard clinical detection, which cannot fully confirm its exact binding effect, in vivo cascade specificity, and independent pathogenic causality in PCOS patients. Additionally, all PCOS patients presented oligo-\/anovulation, whereas healthy controls had regular menstrual cycles; given that circulating miR\u2011382\u20115p levels vary with menstrual cycle phases, the observed downregulation in PCOS serum may partly stem from disrupted cyclic ovulation rather than representing an intrinsic PCOS-specific molecular alteration. Therefore, miR\u2011382\u20115p should be interpreted as a correlative biomarker associated with PCOS phenotypes rather than an independent pathogenic mediator. Conclusions: miR-382-5p regulated the imbalance between insulin-mediated proliferation and apoptosis in KGN cells by directly targeting TOP1, thereby contributing to the progression of PCOS.<\/jats:p>","DOI":"10.1159\/goi\/aczag011","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:47Z","timestamp":1789473767000},"source":"Crossref","is-referenced-by-count":0,"title":["Expression of miR-382-5p in polycystic ovary syndrome and its role in regulating granulosa cell function via targeting TOP1"],"prefix":"10.1159","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,9,25]]},"container-title":["Gynecologic and Obstetric Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/goi\/aczag011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:17:58Z","timestamp":1790925478000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/goi\/aczag011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/goi\/aczag011","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33981424","asserted-by":"subject"}]},"ISSN":["0378-7346","1423-002X"],"issn-type":[{"value":"0378-7346","type":"print"},{"value":"1423-002X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}